UBS Maintains Buy on United Therapeutics, Raises Price Target to $370
United Therapeutics Analyst Ratings
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating
United Therapeutics Analyst Ratings
Komo: Maintaining the United Therapeutics (UTHR.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $280.00 to $300.00.
United Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $300
United Therapeutics Analyst Ratings
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating
Oppenheimer: The United Therapeutics (UTHR.US) rating was maintained, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $375.00 to $400.00.
United Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Regeneron (REGN) and Intuitive Surgical (ISRG)
United Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
Morgan Stanley Maintains Overweight on United Therapeutics, Lowers Price Target to $314
United Therapeutics Analyst Ratings